Skip to main content
$29.57 -$0.25 (-0.8%)

04:00 PM EDT on 04/12/21

Array BioPharma, Inc. (NASDAQ:ARRY)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Current Price $29.57 Mkt Cap $3.8B
Open $29.62 P/E Ratio 61.62
Prev. Close $29.97 Div. (Yield) $0.00 (0.0%)
Daily Range $29.22 - $30.26 Volume 2,216,365
52-Wk Range $22.00 - $54.78 Avg. Daily Vol. 3,007,521

Caps

How do you think NASDAQ:ARRY will perform against the market?

Add Stock to CAPS Watchlist

All Players

258 Outperform
18 Underperform
 

All-Star Players

45 Outperform
2 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:ARRY Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Aiming (< 20)
Submitted August 21, 2015

Many cancer medicine on trial. strong tieup with Astra for selling and research support. loss recovered compared to last year

zzlangerhans (99.06)
Submitted April 25, 2012

It's rather dangerous to red thumb a beaten down cancer or hepatitis biotech, because each one has a finite possibility of rising from the ashes like a Phoenix (or a Pharmasset or Pharmacyclics). Once the market anoints a developmental drug as the… More

NASDAQ:ARRY VS S&P 500 (SPY)

Fools bullish on NASDAQ:ARRY are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about ARRY.

Recs

0
Member Avatar wheelzofsteel (67.03) Submitted: 3/6/2021 11:04:26 PM : Outperform Start Price: $44.74 NASDAQ:ARRY Score: -39.65

Array manufactures ground-mounting systems for solar projects. Their primary product is an integrated system of steel supports, electric motors, gearboxes and electronic controllers that move solar panels throughout the day to maintain an optimal orientation to the sun.

Array's trackers use a patented design (exp. 2030) that allows one motor to drive multiple rows of solar panels through articulated driveline joints. This results in greater reliability, lower installation costs, reduced maintenance requirements and competitive manufacturing costs than competitor designs, which use multiple motors (one for each row).

And customers seem to agree. As of June 30, 2020, there were more than 17 GWs of Array trackers operating worldwide, including over 14 GWs in the U.S., representing nearly 30% of the total utility scale solar generation capacity installed in the U.S.

With governments, utilities, and yieldcos ramping up solar investment in the next decade, Array is going to see a lot of that money. Trackers represent between 10% and 15% of the cost of constructing a ground-mounted solar energy project, and approximately 70% of all ground-mounted solar energy projects constructed in the U.S. during 2019 utilized trackers.

Recs

0
Member Avatar Probablywrong (31.54) Submitted: 1/28/2021 1:48:40 PM : Outperform Start Price: $41.44 NASDAQ:ARRY Score: -38.25

25% market share of 2-D sun-tracking modules for sollar ARRAYs

Seems like a nice secular tailwind

Might just buy and HODL if Solar farms become a priority

Recs

1
Member Avatar Aiming (< 20) Submitted: 8/21/2015 8:49:14 AM : Outperform Start Price: $5.15 NASDAQ:ARRY Score: +370.12

Many cancer medicine on trial. strong tieup with Astra for selling and research support. loss recovered compared to last year

Leaderboard

Find the members with the highest scoring picks in ARRY.

Score Leader

Haugurafpeningum

Haugurafpeningum (34.57) Score: +1,593.44

The Score Leader is the player with the highest score across all their picks in ARRY.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
UncleSachse < 20 10/21/2009 Outperform 1Y $2.09 +1,314.83% +277.51% +1,037.32 0 Comment
EvilUnicorn 40.79 11/17/2009 Outperform 5Y $2.21 +1,241.04% +271.15% +969.90 0 Comment
wes29 55.72 6/10/2011 Outperform 3M $2.40 +1,132.08% +219.47% +912.61 0 Comment
AlpineFirst < 20 3/23/2010 Outperform 3Y $2.47 +1,097.17% +252.37% +844.79 0 Comment
stmbpsak 72.98 10/13/2009 Outperform 3Y $2.47 +1,097.17% +283.17% +814.00 0 Comment
boardwalken65 31.59 2/10/2012 Outperform 3M $2.65 +1,015.85% +206.90% +808.95 0 Comment
ChronicInvestor < 20 10/2/2009 Outperform 3Y $2.45 +1,106.94% +303.51% +803.43 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. 21popsontop 73.26 1/28/2010 Outperform 3Y $2.51 +1,078.09% +276.96% +801.13 1 Comment
robbg52999 72.12 10/12/2009 Outperform NS $2.51 +1,078.09% +282.27% +795.81 0 Comment
taddys 81.49 5/23/2011 Outperform 3Y $2.70 +995.19% +211.90% +783.29 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ARRY.